NASDAQ:DTIL Precision BioSciences (DTIL) Stock Price, News & Analysis $4.20 -0.10 (-2.33%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Precision BioSciences Stock (NASDAQ:DTIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Precision BioSciences alerts:Sign Up Key Stats Today's Range$4.13▼$4.3450-Day Range$4.14▼$5.7552-Week Range$3.61▼$11.09Volume158,073 shsAverage Volume223,267 shsMarket Capitalization$46.58 millionP/E RatioN/ADividend YieldN/APrice Target$47.00Consensus RatingBuy Company OverviewPrecision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Read More… Precision BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreDTIL MarketRank™: Precision BioSciences scored higher than 91% of companies evaluated by MarketBeat, and ranked 99th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPrecision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrecision BioSciences has only been the subject of 1 research reports in the past 90 days.Read more about Precision BioSciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($1.23) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Precision BioSciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.73% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Precision BioSciences has recently decreased by 4.45%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.99 Percentage of Shares Shorted6.73% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Precision BioSciences has recently decreased by 4.45%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment0.28 News SentimentPrecision BioSciences has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Precision BioSciences this week, compared to 2 articles on an average week.Search Interest6 people have searched for DTIL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,963.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Precision BioSciences is held by insiders.Percentage Held by InstitutionsOnly 37.99% of the stock of Precision BioSciences is held by institutions.Read more about Precision BioSciences' insider trading history. Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address DTIL Stock News HeadlinesTransDigm to Buy Simmonds Precision Products From RTX for $765 MillionJune 30 at 7:46 PM | marketwatch.comFounder of Neuralink rival Precision Neuroscience reveals what people often get wrong about brain-implant surgeryJune 29 at 3:52 PM | msn.comNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires "100 times more" power. Chip giant AMD's Chief Executive Lisa Su agrees. She declared that the need for more power is already "orders of magnitude higher" than just last year. We believe this exponential increase in energy required to power AI is going to lead to a gold rush in a small set of stocks critical to this push. | Weiss Ratings (Ad)Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - MorningstarJune 26, 2025 | morningstar.comMDTIL - Precision BioSciences Inc Key Metrics - MorningstarJune 26, 2025 | morningstar.comMPrecision BioSciences Gets FDA's Rare Pediatric Disease Designation For PBGENE-DMD - NasdaqJune 26, 2025 | nasdaq.comDTIL Precision BioSciences, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comPrecision BioSciences stock jumps after FDA grants rare pediatric designationJune 25, 2025 | za.investing.comSee More Headlines DTIL Stock Analysis - Frequently Asked Questions How have DTIL shares performed this year? Precision BioSciences' stock was trading at $3.81 on January 1st, 2025. Since then, DTIL stock has increased by 10.2% and is now trading at $4.20. View the best growth stocks for 2025 here. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($2.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $1.78. The firm earned $0.03 million during the quarter, compared to the consensus estimate of $5 million. Precision BioSciences had a negative trailing twelve-month return on equity of 69.26% and a negative net margin of 42.99%. When did Precision BioSciences' stock split? Shares of Precision BioSciences reverse split before market open on Wednesday, February 14th 2024.The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Precision BioSciences IPO? Precision BioSciences (DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), Luminar Technologies (LAZR), CRISPR Therapeutics (CRSP), Enovix (ENVX), Nokia (NOK) and Ginkgo Bioworks (DNA). Company Calendar Last Earnings5/15/2025Today7/01/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DTIL CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$47.00 High Stock Price Target$60.00 Low Stock Price Target$34.00 Potential Upside/Downside+1,019.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$7.17 million Net Margins-42.99% Pretax Margin-42.99% Return on Equity-69.26% Return on Assets-29.30% Debt Debt-to-Equity Ratio0.45 Current Ratio6.62 Quick Ratio6.62 Sales & Book Value Annual Sales$68.70 million Price / Sales0.68 Cash FlowN/A Price / Cash FlowN/A Book Value$6.87 per share Price / Book0.61Miscellaneous Outstanding Shares11,090,000Free Float10,644,000Market Cap$46.58 million OptionableNo Data Beta1.48 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:DTIL) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.